TRV250 is being developed for the acute treatment of migraine.Learn More
Trevena’s innovative science has led the company to build a pipeline of new chemical entities that are tackling some of the most urgent diseases in CNS and beyond. Three of Trevena’s four novel drug candidates in the pipeline are being studied in close collaboration with the National Institutes of Health.
OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. Additional pipeline assets are in development for migraine, opioid use disorder, and other CNS indications as well as acute respiratory distress syndrome and abnormal clotting related to COVID-19. All of the company’s investigational assets have unique mechanisms of action (MOA) that are designed to optimize receptor pharmacology. The result is a pipeline of innovative therapies targeting well-known receptors, but with a potentially more favorable pharmacological profile than current drugs targeting the same receptor class.
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA||Approved|
|OLINVYK™ (oliceridine) injection||Mu receptor||Acute pain||Approved||Intravenous PC complete||PH1 complete||PH2 complete||PH3 complete||NDA complete||Approved in progress|
|TRV027||AT1 receptor||ARDS / abnormal clotting (COVID-19)||PH2||Intravenous PC complete||PH1 complete||PH2 in progress||PH3 not started||NDA not started||Approved not started|
|TRV250||Delta receptor||Acute migraine||PH1||Oral/Subcutaneous PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Approved not started|
|TRV734||Mu receptor||Opioid use disorder||PH1||Oral PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Approved not started|
|TRV045||S1P receptor||Diabetic neuropathic pain||PC||Oral PC in progress||PH1 not started||PH2 not started||PH3 not started||NDA not started||Approved not started|
G protein-coupled receptors (GPCRs) make up the largest family of transmembrane receptors, with approximately 34% of all U.S. Food and Drug Administration (FDA) approved drugs targeting this receptor class.
Typically, GPCR activation engages broad networks of signaling pathways, which are linked to distinct biological responses. Trevena’s compounds employ a functionally-selective MOA at the receptor site, which enables preferential activation of specific signaling pathways while minimizing activation of others.
Trevena was built from the ground up and founded on the groundbreaking work of Dr. Robert Lefkowitz out of Duke University, who later won the Nobel Prize in Chemistry for his discovery around GPCRs.
Trevena’s approach to GPCR selective agonists, which have tremendous potential for medicines that can improve patient outcomes, has yielded a set of drug candidates with the potential to engage the signaling pathways responsible for therapeutic effect, with reduced activation of the pathways responsible for adverse effects, thus allowing for a more targeted approach to delivering therapeutic benefit.